Archive by Author

Hot Investor Mandate: Canada-Based Firm Invests in Seed to Series B Digital Health Technologies and Medtech Companies With Digital Component 

22 Feb

A venture capital firm with offices in Canada is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. Esplanade is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD $0.5M-2.5M. The firm is currently operating out of its second fund in which it has made five investments after making thirteen investments out of its inaugural fund. Esplanade participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel. 
 
The firm is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. The firm is open to all modalities within digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in developing as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology. 
 
The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat or board observer role as determined by check size on a case-by-case basis. The firm will participate both as lead and co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Life Sciences & Healthcare-Focused VC Invests in Seed Stage Companies in Devices, Diagnostics, and Digital Health

22 Feb

Based in the US, a venture capital firm invests in early-stage life sciences and healthcare. The firm seeks early-stage investment opportunities from seed to series A, generally investing $50k to $1.5M in the initial round, with potential for follow-on investments up to $3M. The firm is focused regionally based companies (those close to their office) but also seek opportunities globally. The firm is open to both leading and co-investing. 
 
The firm invests in medical devices, diagnostics and digital health. The firm is open to considering all subsectors and indications. 
 
While the firm can invest in companies based elsewhere under certain circumstances, the firm is primarily focused on companies in the same state. The firm is active in supporting their portfolio companies and will consider taking a board seat on a case-by-case basis. Additionally, the firm is open to engages with entrepreneurs and founders at a very early stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Asia-Headquartered Investment Firm Seeks Global Opportunities in AI-Empowered Solutions, Devices, and More Addressing Chronic Disease Management

22 Feb

A globally diversified healthcare venture capital firm headquartered in Singapore. The firm’s mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU.  

The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The Case for Life Science Service Providers at RESI Partnering Events

22 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) and our RESI partnering events are a deal-sourcing engine and sales funnel for any service provider with products for early-stage life science companies. The global platform LSN has developed gathers early-stage life science startup entities when they leave academia with a tech transfer license and matches them up with capital investors and licensing partners who do Seed, Series A, and Series B deals over five to ten years. LSN touches and serves twelve thousand global startups (the sell-side) whom we match up with four thousand capital investors and licensing partners (the buy-side). LSN can integrate a service provider into the buy-side and sell-side communities we have built. Below is the program guide from RESI JPM 2024, where LSN hosted six hundred startups and six hundred investors and licensing partners, and every one of those companies needs products and services on their journey to commercialization.

Life Science Nation has over a decade of expertise in helping match startup companies with capital investors and licensing partners. All the scientist-entrepreneurs need to gather knowledge about how to prepare and execute a global partnering campaign. If you are an early-stage life science company translating research, the juxtaposition is academic researchers moving from research into funding and scaling a commercial product. Once funded, that is where LSN’s service provider network enters the picture and can sell its products to the startups. By regularly attending RESI you develop a pipeline of targets for your products.

LSN works with startups to cover the nuts and bolts of preparing and executing a global fundraising campaign. Once they are prepared for a fundraising campaign, LSN provides a global target list of investors and licensing partners that fit their stage of development and product. Service providers play a large role in helping startups succeed, helping them avoid expensive pitfalls. LSN runs five RESI partnering conferences annually around the planet, and RESI provides a platform for startups to leverage and execute their campaign. If you are a service provider, attend RESI events to establish a pipeline of leads and opportunities to meet one-on-one with the early-stage founders.  Many service providers also meet with investors who attend RESI and offer discounted services to the portfolio being managed by the investors.  A win/win for everyone.

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

RESI South Early Bird Rates End Tomorrow

22 Feb

By Cameron Hurlburt, Director of Business Development, LSN

RESI South, March 25, in person at The Whitley Atlanta Buckhead hotel, followed by two days of virtual partnering, March 26-27, early bird rates end tomorrow! Save $300 on registration to RESI South, a partnering conference experience designed to connect early-stage life science and healthcare startups with investors and strategic partners that are a fit for their product and stage of development.

The RESI conference series is unique. It uses a match-based partnering platform designed to take the guesswork out of partnering because it enables users to filter attendees to meet with based on their fundraising needs. To learn more about the partnering platform, join us for a free fundraising webinar, The LSN Event Partnering Process on March 5, 12 PM ET.

Additionally, RESI South will feature conversations with entrepreneurs and investors around specific topics related to the early-stage fundraising ecosystem through expert panels and hosts the Innovator’s Pitch Challenge (IPC), providing opportunities for fundraising executives to pitch directly to a panel of relevant, active investors. IPC applications are accepted on a first-come-first-serve basis, and the IPC application deadline has been extended until Wednesday, February 28.

Whether sourcing elite technology assets or seeking funding from a strategic partner who is a fit for your company, the RESI conference series is a one-stop shop to help you meet your needs. Learn more about what each event has to offer and sign up by February 23 to save!

Register-now-button-new

RESI-South-2024_02062024.

The Right RESI South Registration for You

22 Feb

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti

The RESI South Conference at The Whitley Atlanta Buckhead Hotel on March 25, 2024. The conference, which has served as a catalyst for connecting early-stage life science companies with investors and licensing partners for over a decade will host the event in Atlanta, Georgia for the first time. Life Science Nation anticipates 250+ early-stage investors to register for this event, along with 250+ early-stage startup companies spanning the silos of drugs, devices, diagnostics, and digital health.

Being so early-stage focused, RESI attracts many different types of attendees, and to accommodate that we have a few different registration options. Read through the graph below to figure out what registration option is best for you.

Registration-Type-Chart

Register before Friday, February 23 to save $300 with the Early Bird Rate. Only applicable to some registrations, see prices here.

For additional help in finding your registration type, reach out to the business development team at salescore@lifesciencenation.com to book a meeting so we can assist in figuring out the right registration type for you.

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

Investors and Licensing Partners, Voting with Their Feet Making the Case for RESI South

15 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The secret is out, and LSN sees firsthand that the Southeastern states have been an under served nascent marketplace for discovering early-stage technology assets. Investors have told me that “it’s booming in the South,” with highly competitive technology assets at more reasonable valuations, making for a dynamic marketplace for identifying and investing in early-stage companies across drugs, devices, diagnostics, and digital health.

Over the last six months, I have become familiar with the seven southeast states (GA, VA, NC, SC, AL, TN, and FL) partnered with LSN as co-developers of the RESI South March 25-27th event in Atlanta. A common theme is running through this multi-state alliance: each state seems to have broken the code that to create a life science innovation economy, you need the buy-in and deep participation from academia, industry, and government. In this cross-sector leadership dynamic, the magic happens with a concentration of industry players, a highly educated workforce, and a supportive environment for startups and established companies where innovation can flourish.

Each state in the southeast alliance checks off all the boxes with a preponderance of diverse clusters throughout their region, a high concentration of BioTech, MedTech, and HealthCare companies, and strong support from hospitals, colleges, and research institutions contribute to its dynamic life sciences landscape.

I have witnessed firsthand how each state has a unique and dynamic ecosystem of government, academic, and industry stakeholders working together. Each state’s life sciences industry is not exclusively based in one metro area. There are multiple clusters around the state. This geographical diversity has contributed to the industry’s dynamism.

The last puzzle piece is investment and incentives, and we are seeing a combination of grants, loans, capital infrastructure investments, tax incentives, and workforce programs. These investments have created thousands of jobs and propelled the development of new therapies, devices, and scientific advancements that improve patient health and well-being in the Southeast region and worldwide.

LSN has an investor and licensing partner network of over four thousand entities that leverage LSN and the RESI conference series to identify and invest in companies for their portfolios and product pipelines. RESI South is currently seeing a brisk signup rate and is expecting 300 investors and licensing partners to participate in the one-day face-to-face meeting in Atlanta and the two-day virtual global meeting on March 25- 27.

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

← Older Entries
Newer Entries →